CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 7, 2008--Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing proprietary targeted medicines primarily for cancer treatment, today announced that the Company will release its fourth quarter financial results on Thursday, February 14, 2008 before the market opens. The Company will also hold a conference call on the same day at 9:00 A.M. Eastern time to discuss its financial results, the progress of CUDC-101 and other drug candidates that Curis is developing under its Targeted Cancer Drug Development Platform, Curis' Hedgehog-based product development programs under collaboration with Genentech and Wyeth, as well as additional corporate activities. Daniel Passeri, President and Chief Executive Officer of Curis, will host the call.
To access the live conference call, please call (866) 356-3377 from the United States or Canada or (617) 597-5392 from other locations, shortly before 9:00 A.M. EDT. The conference ID number is 14512747. Replay will be available approximately two hours after the completion of the call and through 5:00 P.M. EST, Thursday, February 28, 2008. To access the replay, please call (888) 286-8010 from the United States or Canada or (617) 801-6888 from other locations and reference the conference ID number 38258302.
About Curis, Inc.
Curis is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies in seeking to create new medicines, primarily for cancer. In expanding the drug development efforts in the field of cancer through the Targeted Cancer Drug Development Platform, the Company is building upon its experiences in targeting signaling pathways in the areas of cancer, neurological disease and cardiovascular disease. For more information, visit the website at www.curis.com.
CONTACT: Curis, Inc.
Michael P. Gray, 617-503-6632
CFO & COO
mgray@curis.com
SOURCE: Curis, Inc.